Percheron Therapeutics (ASX:PER) - Cotización, noticias y análisis

Resumen de acción PER

Percheron Therapeutics Limited se dedica a la investigación y desarrollo de nuevos fármacos antisentido en Australia.

PER fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	1/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 14.75%

Análisis de riesgos

Se prevé que los beneficios disminuyan un promedio de 27.3% al año durante los próximos 3 años

No tiene una capitalización de mercado significativa (A$58M)

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Los accionistas han sido diluidos en el último año

+ 1 riesgos adicionales

Competidores de Percheron Therapeutics Limited

Starpharma Holdings

ASX:SPL

AU$49.4m

Vitura Health

ASX:VIT

AU$74.9m

Little Green Pharma

ASX:LGP

AU$39.2m

Cann Group

ASX:CAN

AU$27.1m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Percheron Therapeutics
Historical stock prices
Current Share Price	AU$0.073
52 Week High	AU$0.11
52 Week Low	AU$0.05
Beta	0.82
1 Month Change	-12.05%
3 Month Change	25.86%
1 Year Change	0%
3 Year Change	-60.54%
5 Year Change	48.98%
Change since IPO	-96.96%

Noticias y actualizaciones recientes

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Nov 13

Recent updates

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Nov 13

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

May 12

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Dec 23

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

Jun 24

We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Mar 11

Will Antisense Therapeutics (ASX:ANP) Spend Its Cash Wisely?

Nov 26

Rentabilidad de los accionistas

	PER	AU Pharmaceuticals	Mercado AU
7D	14.1%	1.0%	-0.3%
1Y	0%	31.1%	6.1%

Rentabilidad vs. Industria: PER obtuvo unos resultados inferiores a los del sector Australian Pharmaceuticals , que el año pasado arrojó un rendimiento del 27.2%.

Rentabilidad vs. Mercado: PER obtuvo unos resultados inferiores a los del mercado Australian, que fue del 5.7% el año pasado.

Volatilidad de los precios

Is PER's price volatile compared to industry and market?
PER volatility
PER Average Weekly Movement	11.0%
Pharmaceuticals Industry Average Movement	10.7%
Market Average Movement	9.0%
10% most volatile stocks in AU Market	17.7%
10% least volatile stocks in AU Market	3.5%

Precio estable de las acciones: El precio de las acciones de PER ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de PER (11%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2000	n/a	James Garner	www.PercheronTx.com

Percheron Therapeutics Limited se dedica a la investigación y el desarrollo de nuevos fármacos antisentido en Australia. Su cartera de productos incluye ATL1102, un inhibidor antisentido de CD49d, que está en fase IIa de ensayo clínico para el tratamiento de la esclerosis múltiple, la distrofia muscular de Duchenne, el asma y otras indicaciones inflamatorias. La cartera de productos de la empresa también incluye el ATL1103, un fármaco antisentido de segunda generación diseñado para bloquear la expresión del receptor de la hormona del crecimiento, reduciendo así los niveles de la hormona factor-I de crecimiento similar a la insulina en la sangre, así como para tratar enfermedades asociadas con la acción excesiva de la hormona del crecimiento que ha completado la fase II de ensayo clínico.

Resumen de fundamentos de Percheron Therapeutics Limited

¿Cómo se comparan los beneficios e ingresos de Percheron Therapeutics con su capitalización de mercado?
Estadísticas fundamentales de PER
Capitalización bursátil	AU$65.81m
Beneficios(TTM)	-AU$10.85m
Ingresos (TTM)	AU$2.29m

28.8x

Ratio precio-ventas (PS)

-6.1x

Ratio precio-beneficio (PE)

¿Está PER sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de PER
Ingresos	AU$2.29m
Coste de los ingresos	AU$56.95k
Beneficio bruto	AU$2.23m
Otros gastos	AU$13.08m
Beneficios	-AU$10.85m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.012
Margen bruto	97.51%
Margen de beneficio neto	-474.51%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado PER a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción PER

Recompensas

Análisis de riesgos

Competidores de Percheron Therapeutics Limited

ASX:SPL

AU$49.4m

ASX:VIT

AU$74.9m

ASX:LGP

AU$39.2m

ASX:CAN

AU$27.1m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Consensus EPS estimates upgraded to AU$0.022 loss

Price target increased by 7.1% to AU$0.30

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Antisense Therapeutics Limited, Annual General Meeting, Nov 15, 2023

Consensus revenue estimates increase by 71%

New minor risk - Financial data availability

Recent updates

Consensus EPS estimates upgraded to AU$0.022 loss

Price target increased by 7.1% to AU$0.30

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Antisense Therapeutics Limited, Annual General Meeting, Nov 15, 2023

Consensus revenue estimates increase by 71%

New minor risk - Financial data availability

New major risk - Financial position

New minor risk - Shareholder dilution

Antisense Therapeutics Limited Receives MHRA Approval for ATL1102 Phase IIb DMD Clinical Trial in UK

We're Not Very Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Rate

Antisense Therapeutics Limited Announces the Appointment of James Garner as Chief Executive Officer, Effective 07 August 2023

Antisense Therapeutics Limited Receives Regulatory Authority Approval from the Turkish Medicines and Medical Device Agency

We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Antisense Therapeutics Limited Commences the Second Phase (Chronic Setting) of Its Program to Study the Effects of an Antisense Oligonucleotide (ASO) to CD49d (Mouse Equivalent of ATL1102) in a LGMDR2 Animal Model of Dysferlin Deficiency

Antisense Therapeutics Limited Reports Initial Positive Muscle Functional Data from A DMD

Antisense Therapeutics Limited Announces Clinical Trial Application Submit for ATL1102 Phase IIb DMD trial conduct in Europe

Less than half of directors are independent

Price target increased to AU$0.31

Antisense Therapeutics Limited Announces Retirement of Mark Diamond as Chief Executive Officer

Antisense Therapeutics Limited Initiates the Process with Contract Research Organisation Pharmaron

Antisense Therapeutics Limited, Annual General Meeting, Nov 17, 2022

Antisense Therapeutics Limited Announces Appointment of Anthony Filippis as Chief Commercial Officer

Price target increased to AU$0.31

Antisense Therapeutics Limited Announces Dosing Commenced in DMD Combination Therapy Study

Consensus forecasts updated

Antisense Therapeutics Limited Intends to Conduct Double-Blind, Placebo Controlled Six Month Dosing Trial of Atl1102 Followed by Six Month Open Label Phase

Full year 2022 earnings released: AU$0.009 loss per share (vs AU$0.015 loss in FY 2021)

We're Hopeful That Antisense Therapeutics (ASX:ANP) Will Use Its Cash Wisely

Antisense Therapeutics Limited Announces Long COVID-19 Study Identifies Novel Blood Markers as Potential Diagnostic and Therapeutic Targets

Antisense Therapeutics Limited Announces Outcomes from Its Collaboration to Study the Neurological Aspects of Long COVID-19

Antisense Therapeutics Limited Announces ATL1102 DMD Clinical Trial Application Submitted in Europe

Antisense Therapeutics Limited Announces Results from First Study of Antisense to CD49d in Limb Girdle Muscular Dystrophy R2 Mouse Model

Antisense Therapeutics Limited Announces the Results from A First Study of Antisense to CD49d in A Limb Girdle Muscular Dystrophy R2 (LGMDR2) Mouse Model

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

Price target increased to AU$0.58

Antisense Therapeutics Limited Announces Dosing Commenced in MCRI Collaboration Animal Study

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Price target increased to AU$0.60

Antisense Therapeutics Limited Announces New Data Supports ATL1102s Broader Clinical Potential

Forecast to breakeven in 2024

Price target increased to AU$0.54

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

Antisense Therapeutics Limited Announces US FDA Feedback on Type C Meeting for ATL1102 in the US

Antisense Therapeutics Limited Announces Manufacture of ATL1102 clinical supplies for Phase IIb trial

We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Antisense Therapeutics Limited Announces the Paediatric Investigation Plan for ATL1102 in DMD Submitted to European Medicines Agency

Antisense Therapeutics Limited Announces Executive Changes

New 90-day high: AU$0.21

Will Antisense Therapeutics (ASX:ANP) Spend Its Cash Wisely?

Antisense Therapeutics Limited, Annual General Meeting, Dec 18, 2020

Antisense Therapeutics Limited Announces Statistically Significant Improvement in Pul2.0 with Atl1102 Treatment in Non-Ambulant Boys with DMD Compared to A Matched Natural History Control

An unknown buyer acquired a 49% stake in Antisense Therapeutics Limited (ASX:ANP) from Opthea Limited (ASX:OPT) for AUD 0.34 million.

Antisense Therapeutics Limited Auditor Raises 'Going Concern' Doubt

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Percheron Therapeutics Limited

28.8x

-6.1x